BDX vs SPRY · P/E 34, rev $21.84B vs rev $89.1M
Becton Dickinson and Company (BDX) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the BDX and SPRY stock pages for the full models.
Not investment advice.